Blood pressure killing the world's workers while banks and drug firms stand idle

In a today’s issue of The Lancet, international health experts call for urgent action from international development banks and pharmaceutical companies to stem the epidemic of blood pressure-related diseases affecting developing countries worldwide.

New findings reveal that each year 8 million people die from heart disease and stroke, the two leading blood pressure-related diseases. The majority of these deaths occur in the developing world where victims are often workers, whose deaths directly result in poverty for families and other dependents. According to the authors these deaths are largely avoidable, but no substantive effort to address this issue has been made by the international development banks or the major drug companies.

Author and Principal Director of The George Institute for International Health in Sydney, Professor Stephen MacMahon said today, “Ten years ago, The Global Burden of Disease Project predicted this epidemic, yet none of the key players who determine priorities for international health investment have made any real effort to address the problem. As a consequence in the last decade, blood pressure related diseases have killed more than 50 million people, disabled many more and taken billions of dollars from the already fragile economies of the developing world.”

Around $US50 billion is spent each year on blood pressure lowering drugs, more than 90% of which is spent in high income countries. “Low- and middle-income regions suffer five times the burden of disease, but have access to less than 10% of the global treatment resource. These diseases affect people of working age in developing countries, and consequently they have major adverse consequences for economic development as well as well as health,” said Professor MacMahon.

Stroke is already the most common cause of death and disability in Asia and is rapidly increasing in other developing regions including Africa. At risk people in these countries could reduce their odds of suffering a stroke by more than one third by taking blood pressure lowering treatments, which are now available for as little as US$ 1 per year. “The cost of avoiding a very large number of fatal or disabling strokes is remarkably small, yet in Africa, for example, there is not one single population-wide initiative aimed at delivering such treatment even to those at the very highest risk. For many people in this situation, the first relevant medical attention is admission to hospital after a stroke, if they survive it,” said Professor MacMahon.

Most low- and middle-income countries lack primary health care services that can provide the long-term care needed for the control of these diseases. The authors admit that tackling this issue is difficult and will require novel approaches that are economically sustainable. This requires investment in health care delivery research, which is often the Cinderella of medical science. “Most international health development agencies and pharmaceutical companies believe the world’s leading health problems are likely to be resolved by the development of clever new drugs. However these will have little relevance if there is no system in place to deliver them,” said Professor MacMahon.

“We are calling on the major players to rethink their policies and strategies. The evidence is clear, and they have the power to bring about major change. They can’t ignore it for any longer,” added Professor MacMahon.

Source: Research Australia

Related stories:

Male cyclists risk sexual problems if they don't choose the right bike
Men who take up cycling in an effort to stay fit, do their bit for the environment or avoid spiralling motoring costs, could be harming their health if they don't choose the right bicycle. That's the stark warning from consultant urological surgeon Mr Vinod Nargund from St Bartholomew's and Homerton Hospitals, London, in the urology journal BJU International.
Overweight, insulin resistant women at greater risk of advanced breast cancer diagnosis, says study
Women who have risk factors commonly associated with Type 2 diabetes also have much greater odds of being diagnosed with an advanced breast cancer, according to research to be presented today.
Hard work while fatigued affects blood pressure
Working hard when fatigued may be admired by many Americans, but it is a virtue that could be harmful to one's health, according to new research by psychologists at the University of Alabama at Birmingham (UAB). The research supports a theory which suggests that exhausted individuals' cardiovascular systems are forced to work harder when they attempt to complete tasks, such as those encountered on the job or at school.

New blood clot guidelines for pregnant women
Blood clot recommendations highlight challenges for pediatric and pre-surgery populations
New evidence-based guidelines address the prevention and management of thrombosis in key patient populations and reinforce recommendations related to the routine use of preventive therapies. Published as a supplement in the June issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), Antithrombotic and Thrombolytic Therapy: ACCP Evidence-Based Clinical Practice Guidelines, Eighth Edition was developed by an international panel of 90 experts and includes more than 700 of the most comprehensive recommendations related to the prevention, treatment, and long-term management of thrombotic disorders. The guidelines include chapters on the challenges in preventing and treating thrombosis in pregnant women and children, and on managing peri- and postoperative patients, while also reinforcing previous guidelines related to the routine use of preventive therapies, including aspirin.
DNA test to revolutionise sheep worm control
CSIRO scientists have moved a step closer to developing a novel DNA test which has the potential to revolutionise management of one of the biggest threats to sheep health in Australia, the barber’s pole worm.

US Pharmacopeia announces revised heparin monographs and reference standards
Standards updated in response to public health threat associated with blood-thinning drug's adulteration with over-sulfated chondroitin
The U.S. Pharmacopeial (USP) Convention announces that revised monographs for heparin sodium and heparin calcium in the United States Pharmacopeia (USP) are now available and official on the USP Web site. The revised monographs are accompanied by two new and two updated official USP Reference Standards. These public standards allow any party—and particularly the Food and Drug Administration (FDA) and manufacturers—to test heparin sodium and calcium drug substances to assure their quality. All drug manufacturers who market heparin in the United States are required to meet these newly revised standards. The heparin monographs were updated in the interest of public health following the deaths of more than 200 people earlier this year. These deaths are suspected to have resulted from the adulteration of the blood thinner with over-sulfated chondroitin, which is derived from the chemical chondroitin and used in dietary supplements.
DNA study unlocks mystery to diverse traits in dogs
Discovery offers potential benefits for dogs and their owners
What makes a pointer point, a sheep dog herd, and a retriever retrieve? Why do Yorkshire terriers live longer than Great Danes? And how can a tiny Chihuahua possibly be related to a Great Dane?
Personalized medicine initiative targets lung cancer
A U.S.-based personalized medicine initiative led by scientists from the Biodesign Institute, Translational Genomics Research Institute (TGen) and Seattle’s Fred Hutchinson Cancer Research Center has secured its first major international collaboration with the government of Luxembourg.

News discussion:

Medicine & Health news